## Product Specification Sheet

<table>
<thead>
<tr>
<th><strong>Product Name:</strong></th>
<th>AMG-706 (Motesanib)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Catalog Number:</strong></td>
<td>C2706</td>
</tr>
</tbody>
</table>

### Technical Information:
- **Chemical Formula:** $\text{C}_{22}\text{H}_{23}\text{N}_5\text{O} \cdot \text{2H}_3\text{PO}_4$
- **CAS #:** 453562-69-1
- **Molecular Weight:** 569.44
- **Purity:** > 99%
- **Appearance:** White solid
- **Solubility:** Soluble in DMSO up to 100mM
- **Chemical Name:** 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-
- **Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.
- **Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

### Handling:
- To make 10 mM stock solution, add 0.176mL of DMSO for each mg of AMG-706 (Motesanib)
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

### Biological Activity:
AMG-706 (Motesanib) is an orally-available, nicotinamide-based, ATP-competitive inhibitor of the VEGFR family of kinases, KIT, and PDGFR with IC50s of 2, 3, and 6 nM (for VEGFR1, VEGFR2, and VEGFR3), 8 nM, and 84 nM, respectively. Besides Ret activity (IC50 = 59 nM), AMG-706 is highly selective against other unrelated kinases, including Src and EGFR. [1] AMG-706 potently inhibits VEGF-induced proliferation of HUVECs with IC50 values of 10 nM. PDGF-induced proliferation and SCF-induced c-Kit phosphorylation was also inhibited at IC50 values of 207 and 37 nM, respectively.

AMG-706 was shown to increase tumor response to radiation in UM-SCC1 and SCC-1483 xenografts of head and neck squamous cell carcinomas. [2]

### Reference:


### To reorder:

### For Technical Support:
[technical@cellagentech.com](mailto:technical@cellagentech.com)

*For research use only, not for clinical or diagnostic use.*